Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: An Italian retrospective study

British Journal of Haematology

Volumn 153, Issue 3, 2011, Pages 351-357

  Iannitto, Emilio ^a   Morabito, Fortunato ^b   Mancuso, Salvatrice ^a   Gentile, Massimo ^b   Montanini, Antonella ^c   Augello, Accursio ^a   Bongarzoni, Velia ^d   D'Arco, Alfonso ^e   Di Renzo, Nicola ^f   Fazzi, Rita ^g   Franco, Giovanni ^a   Marasca, Roberto ^c   Mulè, Antonino ^h   Musso, Maurizio ⁱ   Musto, Pellegrino ^j   Pennese, Elsa ^f   Piccin, Andrea ^k   Rota Scalabrini, Delia ^l   Visani, Giuseppe ^m   Rigacci, Luigi ⁿ  

^a UNIVERSITY OF PALERMO   (Italy)

^b Azienda Ospedaliera   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^e UO Ematologia   (Italy)

^f UO Ematologia e Trapianto di cellule Staminali   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h UO Ematologia   (Italy)

ⁱ Divisione di Ematologia e Trapianto di Midollo Osseo   (Italy)

^j REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^k Ospedale San Maurizio   (Italy)

^l IRCC FPO Candiolo   (Italy)

^m SAN SALVATORE HOSPITAL   (Italy)

ⁿ CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Antineoplastic agents; Bendamustine; Leukaemia; Relapsed chronic lymphocytic leukaemia; Rituximab

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HERPES ZOSTER ENCEPHALITIS; HUMAN; ITALY; LEUKEMIA RELAPSE; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; TREATMENT OUTCOME;

EID: 79954424213     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08597.x     Document Type: Article

References (34)

1. Aivado, M., Schulte, K., Henze, L., Burger, J., Finke, J. & Haas, R. (2002) Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Seminars in Oncology, 29, 19-22.
2. Anderson, J.R., Cain, K.C. & Gelber, R.D. (1983) Analysis of survival by tumor response. Journal of Clinical Oncology, 1, 710-719.
3. Anderson, J.R., Cain, K.C. & Gelber, R.D. (2008) Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. Journal of Clinical Oncology, 26, 3913-3915.
4. Bergmann, M.A., Goebeler, M.E., Herold, M., Emmerich, B., Wilhelm, M., Ruelfs, C., Boening, L. & Hallek, M.J. (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica, 90, 1357-1364.
5. Cheson, B.D. & Rummel, M.J. (2009) Bendamustine: rebirth of an old drug. Journal of Clinical Oncology, 27, 1492-1501.
6. Cheson, B.D., Wendtner, C.M., Pieper, A., Dreyling, M., Friedberg, J., Hoelzer, D., Moreau, P., Gribben, J., Knop, S., Montillo, M. & Rummel, M. (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clinical Lymphoma, Myeloma and Leukemia, 10, 21-27.
7. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society, Series B, 34, 187-220.
8. Ferrajoli, A., Lee, B.N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S., Wierda, W.G., Estrov, Z., Faderl, S., Cohen, E.N., Li, C., Reuben, J.M. & Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291-5297.
9. Fischer, K., Stilgenbauer, S., Schweighofer, C., Busch, R., Renschler, J., Kiehl, M. & Balleisen, L. (2008) Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts), 112, 330.
10. Foon, K.A. & Hallek, M.J. (2010) Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia, 24, 500-511.
11. Forconi, F., Fabbri, A., Lenoci, M., Sozzi, E., Gozzetti, A., Tassi, M., Raspadori, D. & Lauria, F. (2008) Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematological Oncology, 26, 247-251.
12. Giannopoulos, K., Dmoszynska, A., Kowal, M., Wasik-Szczepanek, E., Bojarska-Junak, A., Rolinski, J., Dohner, H., Stilgenbauer, S. & Bullinger, L. (2009) Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia, 23, 1771-1778.
13. Gribben, J.G. (2010) How I treat CLL up front. Blood, 115, 187-197.
14. Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Krober, A., Fostitsch, H.P., Sezer, O., Herold, M., Knauf, W., Wendtner, C.M., Kuse, R., Freund, M., Franke, A., Schriever, F., Nerl, C., Dohner, H., Thiel, E., Hiddemann, W., Brittinger, G. & Emmerich, B. (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. British Journal of Haematology, 114, 342-348.
15. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
16. Hallek, M., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M.A., Catalano, J., Zinzano, P.L., Caligaris Cappio, F., Seymour, J.F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.-M., Eichhorst, B.F., Staib, P., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H., Stilgenbauer, S. & Fischer, K. (2009) First -line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood (ASH Annual Meeting Abstracts), 114, 535.
17. Hamblin, T.J. (2009) Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men? Nature Clinical Practice Oncology, 6, 130-131.
18. Kath, R., Blumenstengel, K., Fricke, H.J. & Hoffken, K. (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. Journal of Cancer Research and Clinical Oncology, 127, 48-54.
19. Knauf, W.U., Lissichkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Fricke, H.J., Huguet, F., Del Giudice, I., Klein, P., Tremmel, L., Merkle, K. & Montillo, M. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 27, 4378-4384.
20. Lamanna, N., Kalaycio, M., Maslak, P., Jurcic, J.G., Heaney, M., Brentjens, R., Zelenetz, A.D., Horgan, D., Gencarelli, A., Panageas, K.S., Scheinberg, D.A. & Weiss, M.A. (2006) Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 1575-1581.
21. Leoni, L.M., Bailey, B., Reifert, J., Bendall, H.H., Zeller, R.W., Corbeil, J., Elliott, G. & Niemeyer, C.C. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research, 14, 309-317.
22. Lin, T.S., Ruppert, A.S., Johnson, A.J., Fischer, B., Heerema, N.A., Andritsos, L.A., Blum, K.A., Flynn, J.M., Jones, J.A., Hu, W., Moran, M.E., Mitchell, S.M., Smith, L.L., Wagner, A.J., Raymond, C.A., Schaaf, L.J., Phelps, M.A., Villalona-Calero, M.A., Grever, M.R. & Byrd, J.C. (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. Journal of Clinical Oncology, 27, 6012-6018.
23. Lissitchkov, T., Arnaudov, G., Peytchev, D. & Merkle, K. (2006) Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. Journal of Cancer Research and Clinical Oncology, 132, 99-104.
24. Moreno, C. & Montserrat, E. (2008) New prognostic markers in chronic lymphocytic leukemia. Blood Reviews, 22, 211-219.
25. Mossner, E., Brunker, P., Moser, S., Puntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jager, C., Strein, P., Fertig, G., Friess, T., Schull, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M.J., Poppema, S., Klein, C. & Umana, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 115, 4393-4402.
26. Motta, M., Wierda, W.G. & Ferrajoli, A. (2009) Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer, 115, 3830-3841.
27. O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. & Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 1414-1420.
28. O'Brien, S., Albitar, M. & Giles, F.J. (2005) Monoclonal antibodies in the treatment of leukemia. Current Molecular Medicine, 5, 663-675.
29. Robak, T., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Geisler, C.H., Montillo, M., Zyuzgin, I., Ganly, P.S., Dartigeas, C., Rosta, A., Maurer, J., Mendila, M., Saville, M.W., Valente, N., Wenger, M.K. & Moiseev, S.I. (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1756-1765.
30. Rummel, M.J., Chow, K.U., Hoelzer, D., Mitrou, P.S. & Weidmann, E. (2002) In vitro studies with bendamustine: enhanced activity in combination with rituximab. Seminars in Oncology, 29, 12-14.
31. Tageja, N. & Nagi, J. (2010) Bendamustine: something old, something new. Cancer Chemotherapy and Pharmacology, 66, 413-423.
32. Wierda, W., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H. & Keating, M. (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4070-4078.
33. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.
34. Zenz, T., Mertens, D., Kuppers, R., Dohner, H. & Stilgenbauer, S. (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature Reviews Cancer, 10, 37-50.